MapLight director buys 14,124 MPLT shares via trust

MapLight Therapeutics director Timothy John Garnett reported an open‑market purchase of Voting Common Stock on February 10, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

MapLight Therapeutics director Timothy John Garnett reported an open‑market purchase of Voting Common Stock on February 10, 2026. Through the Timothy J Garnett Revocable Trust, he bought 14,124 shares at a weighted average price of $17.89 per share, with individual trades between $17.76 and $17.90. Following this transaction, the trust holds 14,124 shares indirectly for him, and he also holds 49,525 shares directly.

Insider Trade Summary

Net Buyer: 14,124 shares

Net Buy 2 txns

Insider Garnett Timothy John

Role Director

Bought 14,124 shs ($253K)

Type	Security	Shares	Price	Value
Purchase	Voting Common Stock	14,124	$17.89	$253K
holding	Voting Common Stock	--	--	--

Holdings After Transaction: Voting Common Stock — 14,124 shares (Indirect, See footnote); Voting Common Stock — 49,525 shares (Direct)

Footnotes (2)

F1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.76 to $17.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote.
F2. The shares are held by the Timothy J Garnett Revocable Trust Dated U/A 09/22/2021, of which the Reporting Person is the sole trustee and has voting and dispositive power.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Timothy John Garnett report at MapLight Therapeutics (MPLT)?

Timothy John Garnett reported an open-market purchase of MapLight Therapeutics Voting Common Stock. On February 10, 2026, he acquired 14,124 shares through his revocable trust, adding to his existing direct shareholdings in the company.

How many MPLT shares did Timothy John Garnett buy and at what price?

He bought 14,124 shares of MapLight Therapeutics Voting Common Stock at a weighted average price of $17.89 per share. Individual trades occurred between $17.76 and $17.90, according to the disclosed weighted-average pricing footnote.

When did the reported MapLight Therapeutics (MPLT) insider purchase take place?

The insider purchase took place on February 10, 2026. On that date, Timothy John Garnett’s revocable trust acquired 14,124 shares of MapLight Therapeutics Voting Common Stock in multiple open-market transactions within the stated price range.

How many MapLight Therapeutics shares does Timothy John Garnett own after this transaction?

After the transaction, his revocable trust holds 14,124 shares indirectly, and he also holds 49,525 shares directly. The filing lists these positions separately, distinguishing between indirect ownership through the trust and direct personal ownership.

How are the newly acquired MPLT shares held for Timothy John Garnett?

The newly acquired 14,124 shares are held by the Timothy J Garnett Revocable Trust dated September 22, 2021. Garnett is the sole trustee of this trust and has both voting and dispositive power over the trust’s MapLight Therapeutics shares.

What does the price range disclosure mean in the MPLT insider purchase?

The weighted average price of $17.89 reflects multiple trades executed between $17.76 and $17.90. The insider notes a willingness to provide full trade-by-trade detail, indicating that the 14,124 shares were bought across several executions within that range.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/12/2026 - 05:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garnett Timothy John

(Last)

(First)

(Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	02/10/2026		P		14,124	A	$17.89⁽¹⁾	14,124	I	See footnote⁽²⁾
Voting Common Stock								49,525	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.76 to $17.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchase at each separate price within the range set forth in this footnote.

2. The shares are held by the Timothy J Garnett Revocable Trust Dated U/A 09/22/2021, of which the Reporting Person is the sole trustee and has voting and dispositive power.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR